Cagrilintide and semaglutide act individually on both EI and EE a, Download Scientific Diagram Amylin based therapies are emerging as promising obesity medications. Eloralintide is a novel, selective amylin receptor agonist in development for weight management, type 2 diabetes and more! Eloralintide, a selective amylin receptor agonist In early studies, a new drug under investigation called eloralintide helped some adults lose nearly 50 pounds in under a year and it's not a GLP 1: https: bit.ly 43nPJnS Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48 week phase 2, multicentre, double blind, randomised, placebo controlled trial The Lancet